Conference
Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC)
Authors
Curran C; Pond GR; Nassar A; Abou Alaiwi S; McGregor BA; Kilbridge KL; Sonpavde G
Volume
38
Publisher
AMER SOC CLINICAL ONCOLOGY
Publication Date
February 20, 2020
Name of conference
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
CA, San Francisco
Conference start date
February 13, 2020
Conference end date
February 15, 2020
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
6
ISSN
0732-183X